Laura J. Esserman MD

General Surgery•San Francisco, CA

Surgical Oncology (Other than Breast)

Associate Professor of Surgery, UCSF

Join to View Full Profile

1600 Divisadero StreetSan Francisco, CA 94143
Phone+1 415-353-7070

Education & Training

Stanford Health Care-Sponsored Stanford UniversityResidency, Surgery, 1983 - 1991
Stanford University School of MedicineClass of 1983

Certifications & Licensure

CA State Medical License 1984 - 2026
HI State Medical License 1989 - 1990
American Board of Surgery Surgery

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2003-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Redbook Magazine: Top Breast Cancer Doctors Castle Connolly, 2001
Super Doctor SuperDoctors.com
Fellow (FACS) American College of Surgeons
Join now to see all

Clinical Trials

Diagnostic Procedures in Women With Locally Advanced Breast Cancer Who Are Receiving Chemotherapy Before Breast Cancer Surgery Start of enrollment: 2002 Feb 01
Completed
Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ Start of enrollment: 2002 Feb 19
Completed
Phase 1, Phase 2
Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer Start of enrollment: 2006 Jul 01
Completed
Phase 2
Study of Ductal Lavage in Women at High Risk for Breast Cancer Start of enrollment: 2002 Aug 01
Completed
Vorinostat in Treating Women With Ductal Carcinoma in Situ of the Breast Start of enrollment: 2009 Jul 01
Completed
Phase 1
Statins and Breast Cancer Biomarkers Start of enrollment: 2005 Jan 01
Unknown status
Phase 2
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Start of enrollment: 2010 Mar 01
RECRUITING
PHASE2
Postoperative Pain Control With Fentanyl Patch in Patients Undergoing Mastectomy and TRAM or DIEP Flap Reconstruction Start of enrollment: 2003 Feb 01
Completed
Phase 4
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients Start of enrollment: 2020 Jul 31
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Balancing risks of surgical complications and positive margins for patients with invasive lobular carcinoma of the breast and elevated BMI: An institutional cohort study.
Israel Falade, Kayla Switalla, Astrid Quirarte, Molly Baxter, Daniel Soroudi
American Journal of Surgery. 2025-03-01
Intratumoral Injection of mRNA-2752 and Pembrolizumab for High-Risk Ductal Carcinoma In Situ: A Phase 1 Nonrandomized Clinical Trial.
Kirithiga Ramalingam, Rachel Woody, Alexa Glencer, Christopher J Schwartz, Hidetoshi Mori
JAMA Oncology. 2025-03-01
Impact of IVF Restriction on Patients With Cancer and Surgeons.
Alexa C Glencer, Laura J Esserman
JAMA Surgery. 2025-03-01

Journal Articles

Breast Conservation and Negative Margins in Invasive Lobular Carcinoma: The Impact of Oncoplastic Surgery and Shave Margins in 358 Patients
Merisa Piper, Jasmine Wong, Hani Sbitany, Cheryl Ewing, Michael Alvarado, Laura Esserman, Robert Foster, Annals of Surgical Oncology

Lectures

The Role of Molecular Biomarkers in the Treatment of the High Risk Patient/I-SPY Trail
San Francisco, CA - 10/25/2014

Other

Clinical features, diagnosis, and staging of newly diagnosed breast cancer
Esserman LJ, Joe BN
http://www.uptodate.com/contents/clinical-features-diagnosis-and-staging-of-newly-diagnosed-breast-c
UpToDate, Wolters Kluwer Health - 2013-01-28
Breast biopsy
Esserman LJ, Joe BN
http://www.uptodate.com/contents/breast-biopsy
UpToDate, Wolters Kluwer Health - 2013-04-01
Diagnostic evaluation of women with suspected breast cancer
Esserman LJ, Joe BN
http://www.uptodate.com/contents/diagnostic-evaluation-of-women-with-suspected-breast-cancer
UpToDate, Wolters Kluwer Health - 2013-04-01

Press Mentions

Evinova, Quantum Leap Healthcare Collaborative Announce PartnershipMarch 25th, 2025
Evinova and Quantum Leap Healthcare Partner to Incorporate Real-Time Remote Patient Monitoring into Breast Cancer Platform TrialMarch 20th, 2025
With DEI in the Crosshairs, ACS Forges Ahead with Ambitious Study of Black WomenMarch 18th, 2025
Join now to see all

Grant Support

WISDOM: A platform to optimize subtype-specific screening and preventionUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2029
WISDOM: A platform to optimize subtype-specific screening and preventionUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2029
The I SPY 2.2 TRIAL: Evolving to Imaging and Molecular Biomarker Response Directed Adaptive Sequential Treatment to Optimize Breast Cancer OutcomesUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2017–2028
The I SPY 2.2 TRIAL: Evolving to Imaging and Molecular Biomarker Response Directed Adaptive Sequential Treatment to Optimize Breast Cancer OutcomesUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2017–2028
The I SPY 2.2 TRIAL: Evolving to Imaging and Molecular Biomarker Response Directed Adaptive Sequential Treatment to Optimize Breast Cancer OutcomesUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2017–2028
RISE UP for Breast CancerUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2025
RISE UP for Breast CancerUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2025
Extending the Diversity, Reach, and Generalizability of the WISDOM StudyUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2020–2025
Surgical Oncology Training GrantUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2020–2025
Surgical Oncology Training GrantUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2020–2025
Surgical Oncology Training GrantUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2020–2025
Surgical Oncology Training GrantUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2020–2025
Integrated Biomarkers To Characterize Breast Cancer RiskNational Cancer Institute2004–2009